During a period of rapid fluctuation in the intravenous iron market, there was increased use of a more expensive drug that afforded providers additional revenue.
Bryan C. Hambley, MD, MPH
Advertisement
Articles by Bryan C. Hambley, MD, MPH
Advertisement
Latest Updated Articles
- Payment Incentives and the Use of Higher-Cost Drugs: A Retrospective Cohort Analysis of Intravenous Iron in the Medicare Population
Published: December 9th 2020 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
2
FDA Approves Elinzanetant, a Hormone-Free Option for Hot Flashes in Menopause
3
GLP-1 Receptor Agonists May Improve Rheumatoid Arthritis Symptoms
4
Elinzanetant Shows Strong 52-Week Safety for Vasomotor Symptoms: James Simon, MD
5
